Page 6 - Systemic Sclerosis News Today

Data from Certa Therapeutics' Phase 2 clinical trial with development candidate FT011 demonstrates clinically meaningful improvements for more than 60 percent of patients with scleroderma after 12 weeks of treatment; Clinically meaningful improvements were reported in CRISS (the key composite endpoint for systemic sclerosis) lung function, SHAQ-DI and Physician Global Assessment; The trial results also showed FT011 to be safe and well tolerated in this patient population; FT011 is a novel, f...

A novel, first-in-class oral therapy showed meaningful improvement in over half of scleroderma patients in a Phase II trial.

Investegate announcements from GSK PLC, Benlysta granted Orphan Drug Designation by US FDA

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Benlysta (belimumab), a B-cell inhibiting monoclonal antibody, for the potential treatment of systemic sclerosis. GSK plans to initiate a phase II/III trial of belimumab for systemic ...

/PRNewswire/ -- The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, is proud to...

REGULATED INFORMATION Mont-Saint-Guibert, Belgium, January 27, 2023, 7am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company...

Guidelines could tailor cardiovascular risk scores by using a multiplier of 2.5 for systemic sclerosis, 2.0 for lupus, and 1.5 for any other rheumatic disease.

More than 110 pulmonologists, rheumatologists and radiologists and three international speakers focused on the latest scientific guidelines to improve the clinical outcomes for patients living with rare respiratory conditions at a Dubai event.

/PRNewswire/ -- Systemic Sclerosis (Scleroderma) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top...

Systemic sclerosis, also known as scleroderma, is a rare and complex autoimmune connective-tissue disease. Once considered an untreatable and unpredictable condition, research advancements have improved our understanding of its disease pathogenesis and clinical phenotypes and expanded our treatment armamentarium. Early and accurate diagnosis is essential, while ongoing efforts to risk stratify patients have a central role in predicting both organ involvement and disease progression. A holistic a...